title: Repeated administration of alpha-hederin results in alterations in maternal zinc status and adverse developmental outcome in the rat.
abstract: The administration of alpha-hederin, an inducer of metallothionein, results in a secondary zinc deficiency that may be an important maternally mediated mechanism of developmental toxicity. Previous studies have shown adverse developmental outcome with a single administration of alpha-hederin to rats on gestation day (GD) 8 or 11. The objective of this study was to determine whether dosing of alpha-hederin throughout organogenesis would result in a sustained elevation of maternal hepatic metallothionein and subsequent developmental abnormalities. Rats were administered dosage levels of 0 (vehicle only), 20, or 30 mumol/kg from GD 6-15. Maternal hepatic metallothionein levels were 10-fold higher on GD 16 in the treatment groups than the controls. Consequently, liver zinc concentrations increased 60% and 54%, whereas plasma levels decreased 23% and 33% in the 20 and 30 mumol/kg treatment groups, respectively. At GD 20, mean fetal weights of the treatment litters were 11% less than control litters. The administration of alpha-hederin resulted in a threefold increase in the number of offspring that exhibited developmental abnormalities, including visceral and skeletal malformations. Following an oral pulse of 65Zn subsequent to treatment with 0 or 20 mumol/kg of alpha-hederin, the distribution of 65Zn to the liver of treated dams was twice that of controls, whereas the radiolabeled zinc apportioned to the decidua and uterus decreased by 44%. Furthermore, the 65Zn detected in the embryos from treated dams was 70% lower than in embryos from control dams. In conclusion, low doses of a metallothionein inducer administered to the dam from GD 6-15 resulted in a sustained elevation of hepatic metallothionein and a subsequent redistribution of zinc leading to a decrease in the zinc available to the embryo and ultimately to adverse development of the offspring. Repeated dosing throughout organogenesis, as required in regulated safety assessment testing, increased the severity of the effects previously observed with single large dosages of the toxicant administered during midgestation.
authors.affiliation: Miami Valley Laboratories, Procter & Gamble Co., Cincinnati, Ohio 45239, USA.
authors.forename: J Y
authors.initials: JY
authors.lastname: Duffy
authors.forename: D
authors.initials: D
authors.lastname: Baines
authors.forename: G J
authors.initials: GJ
authors.lastname: Overmann
authors.forename: C L
authors.initials: CL
authors.lastname: Keen
authors.forename: G P
authors.initials: GP
authors.lastname: Daston
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D008431:Maternal-Fetal Exchange; D008668:Metallothionein / Q000096:biosynthesis*; D009828:Oleanolic Acid / Q000031:analogs & derivatives*; D011247:Pregnancy; D011256:Pregnancy Outcome; D051381:Rats; D017207:Rats, Sprague-Dawley; D012503:Saponins / Q000633:toxicity*; D015032:Zinc / Q000172:deficiency*; D015037:Zinc Radioisotopes
chemical_list: D012503:Saponins; D015037:Zinc Radioisotopes; C010177:beta-hederin; D009828:Oleanolic Acid; D008668:Metallothionein; D015032:Zinc